Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 525

Results For "SSI"

5502 News Found

Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab
Drug Approval | September 01, 2021

Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab

JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis


SK Bioscience and GSK start Phase 3 trial of an adjuvanted COVID-19 vaccine candidate
Drug Approval | September 01, 2021

SK Bioscience and GSK start Phase 3 trial of an adjuvanted COVID-19 vaccine candidate

Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine


Metropolis Healthcare opens new testing centre in Thalassery, Kerala
Healthcare | September 01, 2021

Metropolis Healthcare opens new testing centre in Thalassery, Kerala

The lab will offer about 4,000 different tests ranging from basic to high-end molecular diagnostic tests


Sher-I-Kashmir Institute of Medical Sciences and Medtronic partner to open Surgical Skills Lab
Digitisation | September 01, 2021

Sher-I-Kashmir Institute of Medical Sciences and Medtronic partner to open Surgical Skills Lab

The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise


US FDA grants Lantern Pharma additional Orphan Drug tag for LP-184
Biotech | August 31, 2021

US FDA grants Lantern Pharma additional Orphan Drug tag for LP-184

The drug is also intended for the treatment of glioblastoma multiforme


Sun Pharma to commercialise Winlevi in the US and Canada
News | August 31, 2021

Sun Pharma to commercialise Winlevi in the US and Canada

Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago


Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis
Biotech | August 31, 2021

Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis

Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old


Union Minister Sonowal announces major plans for promoting Ayush in NE
Policy | August 30, 2021

Union Minister Sonowal announces major plans for promoting Ayush in NE

A sum of Rs 70 crores and Rs 10 crores for a new Ayurvedic college in Assam and upgradation of the ayurvedic college in Guwahati respectively


Visby Medical receives FDA approval and CLIA waiver for PCR sexual health test
Drug Approval | August 30, 2021

Visby Medical receives FDA approval and CLIA waiver for PCR sexual health test

The Visby Medical sexual health click test is the first instrument-free PCR test for the detection of chlamydia, gonorrhoea and trichomonas, with results available within 30 minutes, during the patient visit


Roche withdraws the US accelerated approval for Tecentriq
Drug Approval | August 28, 2021

Roche withdraws the US accelerated approval for Tecentriq

Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider